GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Owner Earnings per Share (TTM)

Medigen Biotechnology (ROCO:3176) Owner Earnings per Share (TTM) : 0.08 (As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Medigen Biotechnology's Owner Earnings per Share (TTM) ended in Jun. 2024 was NT$0.08. It's Price-to-Owner-Earnings ratio for today is 457.5.


The historical rank and industry rank for Medigen Biotechnology's Owner Earnings per Share (TTM) or its related term are showing as below:

ROCO:3176' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 20.43   Med: 561.33   Max: 971.59
Current: 491.33


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Medigen Biotechnology was 971.59. The lowest was 20.43. And the median was 561.33.


ROCO:3176's Price-to-Owner-Earnings is ranked worse than
96.97% of 165 companies
in the Biotechnology industry
Industry Median: 36.35 vs ROCO:3176: 491.33

Medigen Biotechnology's Earnings per Share (Diluted) for the three months ended in Jun. 2024 was NT$0.08. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-3.11. It's PE Ratio (TTM) ratio for today is At Loss.

Medigen Biotechnology's EPS without NRI for the three months ended in Jun. 2024 was NT$0.10. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-3.01. It's PE Ratio without NRI ratio for today is At Loss.


Medigen Biotechnology Owner Earnings per Share (TTM) Historical Data

The historical data trend for Medigen Biotechnology's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Owner Earnings per Share (TTM) Chart

Medigen Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.64 -3.08 -6.71 -3.26 0.07

Medigen Biotechnology Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.49 1.62 0.07 -1.20 0.08

Competitive Comparison of Medigen Biotechnology's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, Medigen Biotechnology's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Biotechnology's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Medigen Biotechnology's Price-to-Owner-Earnings falls into.



Medigen Biotechnology Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Medigen Biotechnology's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -433
Depreciation, Depletion and Amortization 176
Change In Deferred Tax 0
5Y Average of Maintenance Capital Expenditure 118
Change In Working Capital 387
Shares Outstanding (Diluted Average) 149

1. Start with "Net Income" from income statement. Medigen Biotechnology's Net Income for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-433 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Medigen Biotechnology's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Jun. 2024 was NT$176 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Medigen Biotechnology's Change In Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2024 was NT$0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = NT$118 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Medigen Biotechnology's 5-Year Average Maintenance Capital Expenditure = NT$118 Mil

5. "Change In Working Capital" is from cashflow statement. Medigen Biotechnology's Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2024 was NT$387 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Medigen Biotechnology's Shares Outstanding (Diluted Average) for the months ended in Jun. 2024 was 149.338 Mil.

Medigen Biotechnology's Onwer Earnings Per Share for Jun. 2024 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -433.067 +175.745+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-118.1624+386.743)/149.338
=0.08

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=36.60/0.08
=457.5

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Medigen Biotechnology Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigen Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is a biopharmaceutical company engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The company has four segments: Nucleic acid department: segment, which derives maximum revenue, is responsible for services of testing reagents, instruments and inspection on behalf of others; New drug and vaccine research and development segment: responsible for the development and relevant services of new drugs and vaccine; Cytotherapy department: responsible for research and development and relevant services of cytotherapy; and Generic drug, aesthetic medicine product and dietary supplement segment is responsible for production and sales and relevant services of western medicine, aesthetic medicine product and dietary supplement.

Medigen Biotechnology Headlines

No Headlines